ARTICLE | Company News
Astellas submits telavancin MAA
October 29, 2009 1:23 AM UTC
Astellas Pharma Inc. (Tokyo:4503) submitted an MAA to EMEA for telavancin to treat nosocomial pneumonia, including ventilator-associated pneumonia, and complicated skin and soft tissue infections (cSS...